Christopher Gibson, Chief Executive Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 277,148 shares at $6.04 ($1.7M) on 2025-03-27, disclosed to the SEC on 2025-03-28.
Scheduled sale ($1.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.04 | 138,574 | $837K | 50.0% |
| 2 | $6.04 | 138,574 | $837K | 50.0% |
| Total | $6.04 avg | 277,148 | $1.7M | 100% |
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-04-08 | $124K | — | Filing → |